Introduction {#sec1_1}
============

Brain metastases (BM) are a relatively frequent but serious complication in patients with non-small cell lung cancer (NSCLC). Although the most reliable methods to control intracranial metastases are surgical resection or stereotactic radiosurgery, whole brain radiotherapy (WBRT) is considered the standard option for cases of multiple metastases or out of concern for invisible metastasis. However, possible late neurologic sequelae of WBRT make physicians anxious. Therefore, more customized treatment strategies for BM are required in order to avoid late complications of WBRT. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have shown remarkable response rates for intracranial lesions as well as extracranial lesions in NSCLC patients harboring EGFR activating mutations. Here, we report 3 cases that showed complete regression of intracranial lesions after treatment with only gefitinib, without WBRT. Furthermore, we summarize previous studies supporting a treatment strategy that uses an upfront EGFR-TKI without radiotherapy.

Case Report {#sec1_2}
===========

Case 1 {#sec2_1}
------

A 60-year-old man with a history of smoking presented at our hospital due to back pain and a chest X-ray abnormality. Lung adenocarcinoma was diagnosed with a bronchoscopic biopsy, and whole body positron emission tomography-computed tomography (PET-CT) showed multiple metastases on the lumbar spine and pelvic bone. The tumor was found to have an EGFR mutation (exon 19 deletion) and sequential brain magnetic resonance imaging (MRI) revealed multiple tiny enhancing nodules in the left occipital lobe and cerebellum. Gefitinib (250 mg/day) was administered and radiotherapy was performed on the lumbar vertebra. WBRT was deferred due to the absence of symptoms. One month after gefitinib treatment was initiated, interval regression of BM was identified on a follow-up brain MRI. After another 3 months, metastatic lesions were not discernible on a follow-up brain MRI (fig. [1a](#F1){ref-type="fig"}).

Case 2 {#sec2_2}
------

A 72-year-old woman without a history of smoking presented with supraclavicular lymphadenopathy. An incisional biopsy of the lymph node was performed, and the pathologic result was adenocarcinoma with cytokeratin-7 (CK-7) and thyroid transcription factor-1 (TTF-1) positivity on immunohistochemical staining. The tumor was harboring an EGFR mutation (exon 19 deletion). Whole body PET-CT showed multiple bone metastases with mediastinal lymphadenopathy. Brain MRI identified well-defined enhancing round nodules on the right frontal and left parietal lobes. She received gefitinib (250 mg/day) and palliative radiotherapy for the painful pelvic bone metastases. WBRT was put off because she did not complain of neurologic symptoms. A brain MRI performed 6 months later showed interval regression of multiple BM. The metastatic nodules disappeared after another 3 months (fig. [1b](#F1){ref-type="fig"}).

Case 3 {#sec2_3}
------

A 74-year-old woman without a history of smoking presented with a scalp mass. An incisional biopsy performed on the scalp mass revealed adenocarcinoma with CK-7 and TTF-1 positivity on immunohistochemical staining. An EGFR mutation analysis found an exon 21 L858R point mutation. Whole body PET-CT detected a lung mass and multiple bone metastases. Brain MRI identified several tiny enhancing nodules on both cerebral hemispheres. After 5 months of gefitinib treatment (250 mg/day), a follow-up brain MRI showed no brain parenchymal metastatic lesions (fig. [1c](#F1){ref-type="fig"}).

Discussion {#sec1_3}
==========

BM are a relatively frequent and grave complication of NSCLC. Considering prolonged overall survival results from superior systemic treatment, the incidence of BM is expected to rise. Therefore, treatment strategies for BM need to commensurate with the development of systemic treatments. Because of the marginal effect of systemic chemotherapy, radiotherapy or surgery has been considered a standard treatment for BM from lung cancer. However, encouraging intracranial effects of some systemic chemotherapeutic agents, including EGFR-TKIs, have been gradually proposed \[[@B1]\]. In particular, in a few case reports and retrospective/prospective studies \[[@B2], [@B3], [@B4]\], outstanding effects of EGFR-TKIs on BM have been reported in patients harboring EGFR activating mutations. Considering that NSCLC is a relatively radioresistant malignancy and the possibility of late neurologic sequelae of WBRT, EGFR-TKIs are considered a promising option on central nervous system metastases from lung adenocarcinoma. However, there is no consensus on an optimal TKI agent, the reliability of EGFR mutation status of the primary tumor as a surrogate marker of EGFR mutation status of BM, temporal arrangement of WBRT and EGFR-TKI treatment or management of intracranial local failure after TKI treatment \[[@B5]\]. Among them, substitution of WBRT with an EGFR-TKI as an initial treatment for BM has been a subject of concern.

Firstly, it has been proposed that EGFR-TKIs should be administered as concomitant agents with WBRT for BM in patients with NSCLC because blocking EGFR signaling in vitro has been known to sensitize cancer cells to the effects of radiation. In practice, Zeng et al. \[[@B6]\] compared the efficacy of gefitinib alone with gefitinib plus concomitant WBRT and insisted that concurrent treatment improves response rate and overall survival. However, the EGFR mutation status of the enrolled patients was not reported. Moreover, the response rate in the patient group treated with concomitant gefitinib and WBRT was not significantly higher than that of previously reported studies which targeted only patients harboring EGFR mutations treated with EGFR-TKI alone. A few subsequent studies including erlotinib also showed similar results \[[@B7], [@B8]\]. Therefore, the additional benefit of concomitant radiation is uncertain, particularly in NSCLC patients harboring EGFR activating mutations.

Furthermore, we searched for and summarized studies regarding the intracranial response rate of EGFR-TKIs with or without WBRT in lung adenocarcinoma (table [1](#T1){ref-type="table"}). Based on our summary, the response rate to EGFR-TKI only treatment was comparable to that of EGFR-TKI plus WBRT concomitant therapy. Central nervous system failure interval of the concurrent treatment group was not longer than that of the EGFR-TKI only treatment group. However, we should consider the potential harmful effect of WBRT on neurologic function. Assessing impairment in neurocognitive function in patients treated with WBRT is difficult, and to estimate net effect of WBRT on neurocognitive function, many variables such as other oncological treatments, including chemotherapy, anticonvulsants, opioids and neurocognitive dysfunction caused by metastases itself, should be considered. Therefore, controversy remains about how significant the detrimental effect of WBRT is on neurocognitive function.

However, many studies supported these concerns with reasonable evidence \[[@B9]\]. In particular, 1 study aimed at patients without BM who received prophylactic cranial irradiation showed a significant decline in neurocognitive function compared with that in the observation group \[[@B10]\]. Along with those results, various efforts such as focal therapy-oriented strategy, dose per fraction reduction for prophylactic cranial irradiation and hippocampal-sparing radiotherapy are being discussed to avoid or reduce late complications of WBRT \[[@B11]\]. Therefore, there is no reason that upfront WBRT should be performed at the risk neurologic complications if there are effective alternatives. Some oncologists justify upfront WBRT for several reasons, even in patients harboring EGFR activating mutations. Hirata et al. \[[@B12]\] reported that acquired resistance to TKIs triggers cross-resistance to radiotherapy, whereas TKI-naive patients with an EGFR mutation exhibit better response to brain radiotherapy than those with wild-type EGFR. However, continuing TKI after progression, increasing the dose of TKI or switching to a second-generation TKI after acquired resistance to a TKI can be considered a solution for diminished radiosensitivity \[[@B13], [@B14]\].

In addition, other clinical indicators predicting a favorable intracranial response to TKIs except EGFR mutations should be investigated to select appropriate patients who can avoid upfront WBRT. Although there are no statistical data, BM size is thought to be an important predictive factor. Based on previous reports that analyzed TKI concentration in cerebrospinal fluid, TKIs were not free from the blood-brain barrier either. That is, the blood-brain barrier acts as an obstacle for TKIs to penetrate the brain parenchyma \[[@B15]\]. Consequently, the size of the metastasis is thought to be affected by the concentration of TKIs and acts as a predictive factor of intracranial response. In that sense, remarkable intracranial control in our cases was also attributed to the small size of the metastases.

In conclusion, BM is not an uncommon complication in patients with NSCLC. A stratified treatment approach is required to balance optimal intracranial disease control and neurologic complications. EGFR-TKI treatment and withholding WBRT is a feasible option in asymptomatic patients with small metastatic nodules harboring an EGFR mutation.
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![Brain MRI (**a--c**) of 3 NSCLC patients before (top row) and after (bottom row) gefitinib treatment. **a** On contrast enhanced T1 weighted image, a small peripheral enhancing nodule in the left occipital lobe is identified (arrow). **b** A small, well-defined enhancing round nodule in the left occipital lobe is identified (arrow). **c** A small enhancing nodule in the right periventricular deep white matter is identified (arrow).](cro-0007-0149-g01){#F1}

###### 

Reports about intracranial response to EGFR-TKIs without WBRT in lung cancer patients (adenocarcinoma)

  Author                            Pt   TKI agent used                                          WBRT                               Intracranial response rate, %   CNS failure interval, ms   EGFR mutation
  --------------------------------- ---- ------------------------------------------------------- ---------------------------------- ------------------------------- -------------------------- -----------------------------------------
                                                                                                                                                                                               
  Kim et al. (2009) \[[@B2]\]       23   gefitinib 250 mg (n = 16) or erlotinib 150 mg (n = 7)   ND                                 73.9                            19.3                       confirmed (Y)
                                                                                                                                                                                               
  Park et al. (2012) \[[@B4]\]      28   gefitinib 250 mg (n = 22) or erlotinib 150 mg (n = 6)   ND                                 83                              12.6                       confirmed (Y)
                                                                                                                                                                                               
  Iuchi et al. (2013) \[[@B7]\]     41   gefitinib 250 mg                                        ND                                 87.8                            14.5                       confirmed (Y)
                                                                                                                                                                                               
  Zeng et al. (2012) \[[@B6]\]      90   gefitinib 250 mg                                        done (n = 45)(40 Gy) ND (n = 45)   done: 64.4 ND: 26.7             done: 10.6 ND: 6.57        unconfirmed
                                                                                                                                                                                               
  Welsh et al. (2013) \[[@B8]\]     40   erlotinib 150 mg                                        done (35 Gy)                       86                              8.0                        Y (n = 8) N (n = 9) unconfirmed (n =23)
                                                                                                                                                                                               
  Zhuang et al. (2013) \[[@B16]\]   23   erlotinib 150 mg                                        done (30 Gy)                       95.65                           Y: 11.2 N: 9.6             Y (n = 11) N (n = 12)

Pt = Number of patients; Y = yes; N= no; ND = not done.
